Amorfix Life Science (ARFXF) 0.1001 $ARFXF ProMIS

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amorfix Life Science (ARFXF) 0.1001 $ARFXF

ProMIS Neurosciences to Present at CNS Diseases World Summit 2016
PRWeb - Wed Sep 14, 6:04AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company" today announced that the Company has been invited to present at GTCBio's CNS Diseases World Summit 2016 to be held at the Hyatt Boston Harbor on September 12-15, 2016 in Boston, MA.

ProMIS Neurosciences announces positive validation of novel antibody therapeutic candidates for Alzheimer's disease
PRWeb - Tue Sep 13, 6:07AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" , a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that at least three of its antibody therapeutic candidates targeting prion-like strains of Amyloid beta (Aβ) have successfully completed validation in cadaveric brain tissue and cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD). The successful product candidates demonstrated the desired target profile of binding to brain tissue extracts and CSF from AD patients while not binding to plaque, as evidenced by microscopic examination (immunohistochemistry) of AD brain tissue. These monoclonal antibody (mAb) therapeutics have been designed to selectively bind only to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Aβ, which are widely believed to play a key role in the development and progression of AD.

ProMIS Neurosciences to Present at Rodman & Renshaw 18th Annual Global Investment Conference
PRWeb - Mon Sep 12, 6:09AM CDT
ProMIS™ Neurosciences, Inc.

ProMIS Neurosciences Announces Second Quarter 2016 Results
PRWeb - Fri Aug 12, 6:05AM CDT
Recent Corporate Highlights

ProMIS Neurosciences' Chief Science Officer Dr. Neil Cashman Presenting as an Invited Speaker at the 2016 Zing Propagation in Neurodegenerative Disease Conference
PRWeb - Thu Aug 11, 6:06AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" , a company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced that its Chief Science Officer Dr. Neil Cashman is presenting today as an invited speaker at the Zing Propagation in Neurodegenerative Disease Conference held in Dublin, Ireland between August 8-11, 2016. Dr. Cashman's oral presentation is entitled "Prion-like Propagation of SOD1 Misfolding in Amyotrophic Lateral Sclerosis (ALS)".

ProMIS Neurosciences Reports Highlights from the 2016 Alzheimer's Association International Conference
PRWeb - Wed Aug 03, 6:10AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" , a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today reported highlights from the recent Alzheimer's Association International Conference (AAIC) meeting, held in Toronto, Canada, from July 23 to 28, 2016.

ProMIS Neurosciences Announces Results in Two Presentations at the 2016 Alzheimer's Association International Conference
PRWeb - Thu Jul 28, 6:05AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" , a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced results in two presentations on its recent therapeutic developments at the Alzheimer's Association International Conference on July 27th, 2016 in Toronto, Ontario, Canada.

ProMIS Neurosciences Announces Identification of Multiple Product Candidates Targeting Alzheimer's Disease
PRWeb - Thu Jun 02, 6:09AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" , a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that multiple unique therapeutic candidates have successfully completed the screening stage of validation, and will be further developed as potential treatments for Alzheimer's disease (AD). These monoclonal antibody (mab) therapeutics selectively bind to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Amyloid beta (Aβ), which are widely believed to play a key role in the development and progression of AD.

ProMIS Neurosciences announces identification of multiple product candidates targeting Alzheimer's disease
CNW Group - Thu Jun 02, 6:00AM CDT
Novel therapeutic candidates designed to specifically target the neurotoxic, prion-like strains of misfolded Amyloid beta
PMN.TO: 0.14 (+0.01)

ProMIS Neurosciences Announces First Quarter 2016 Results
PRWeb - Wed May 11, 6:10AM CDT
Recent Corporate Highlights

ProMIS Neurosciences announces first quarter 2016 results
CNW Group - Wed May 11, 6:00AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company" today announced its operational and financial results for the three months ended March 31, 2016.
PMN.TO: 0.14 (+0.01)

ProMIS Neurosciences announces identification of a fourth novel therapeutic target for Alzheimer's disease
CNW Group - Thu May 05, 6:00AM CDT
Novel target is fourth in a series of potential targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's
PMN.TO: 0.14 (+0.01)

Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 3.27 (-0.03), DRNA: 4.23 (-0.07), INCY: 88.98 (-0.29), LLY: 81.16 (-0.13), STML: 10.58 (+0.35), SNTA: 0.34 (+0.07), ANTH: 3.19 (+0.05), EXEL: 14.89 (+0.15)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 55

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 73

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 105

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 79

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
PepsiCo Locks In Hyatt's 700-Property U.S. Supply Deal

Updated Category News Views 76

A hotel minibar is a lousy place to hunt for glamour, but it is a terrific place to spot durable distribution. PepsiCo has renewed its U.S. food and beverage relationship with Hyatt for 10 years, covering more than 700 properties. Nobody should pretend a hotel contract transforms a company with nearly $94 billion in 2025 revenue. Still, this is the sort of unflashy...

Continue Reading
PostalAnnex Adds Roseville Store as Owners Reach Three

Updated Category News Views 97

A third storefront from the same operators says more than a ribbon-cutting ever will. Aarondeep Hira and Manraj Sangha have opened a PostalAnnex in Roseville, California, their third Sacramento-area location after earlier operations in Sacramento and Antelope. For a franchise system, repeat ownership is the part worth noticing. It is not a guarantee of booming sales, and...

Continue Reading
Genome-Written XDP Mice Could Sharpen Drug Research

Updated Category News Views 60

Seventy-eight thousand DNA letters changed the pace of a cruel little-known disease story. NYU Langone researchers inserted a human disease-linked stretch of genetic material into mice and produced an accelerated model of X-linked dystonia-parkinsonism, or XDP. That is a serious laboratory accomplishment, not a cure announcement, and it deserves to be read with both...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 60

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 122

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading

Top 5 Most Recently Viewed Articles

Immutable Expands Web3 Gaming Influence in Major Conference

Updated Category News Views 257

Immutable's Growing Presence at GDC 2025 Immutable is affirmatively stepping into the spotlight at the upcoming Game Developers Conference (GDC) 2025, a pivotal event that congregates the brightest minds of the gaming industry. With collaborations alongside notable partners such as RavenQuest, Polygon Labs, Sequence, and MetaGravity, Immutable is ready to showcase its...

Continue Reading
Rathbones Group's Influence on Empiric Student Property Plc

Updated Category News Views 239

Understanding Public Opening Position Disclosures Public opening position disclosures are essential for maintaining transparency in financial markets. This process is especially important for stakeholders interested in relevant securities, particularly when holdings exceed 1%. Disclosures must provide critical information on who owns shares and any short positions related...

Continue Reading
Rapid Nexus Achieves Historic Milestone in Wound Care Technology

Updated Category News Views 389

Rapid Nexus Receives FDA Clearance for Hemastyl Gel The FDA 510(k) clearance for its Hemastyl gel device marks the first technology that has treated the tissue surrounding chronic wounds and prevented numerous amputations. On a significant day in the realm of wound care, Rapid Nexus, a pioneering California-based med-tech company, has announced the receipt of FDA 510(k)...

Continue Reading
Grainger Approves Substantial Dividend to Shareholders

Updated Category News Views 131

Grainger's Commitment to Shareholders Through Dividends W.W. Grainger, Inc. (NYSE: GWW) has recently taken significant steps to reward its investors. The board of directors has officially approved a cash dividend of $2.26 per share. This strong move by Grainger underscores its commitment to providing long-term value to its shareholders. Details of the Dividend...

Continue Reading
Grupo Aeroportuario del Pacífico Secures New Credit Line Deal

Updated Category News Views 236

Grupo Aeroportuario del Pacífico Unveils Expanded Credit Line Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (PAC), a prominent player in the Mexican aviation sector, has recently announced a significant refinancing of its credit arrangements. The company has successfully secured a USD $40 million credit line from Banco Nacional de México, S.A. (Banamex). This...

Continue Reading